The OPTI-STEM project aims to optimize the production of MSCs in order to democratize access to them and thus allow the diversification of therapeutic applications of this type of cells and their derivatives (exosomes, etc.). To achieve this objective, the R&D consortium led by Cell-Easy has obtained public funding of more than 7 million euros as part of the "Biotherapies and Bioproduction of Innovative Therapies" acceleration strategy, operated on behalf of the French government by Bpifrance.